AR102879A1 - Métodos para el tratamiento de tumores cerebrales - Google Patents
Métodos para el tratamiento de tumores cerebralesInfo
- Publication number
- AR102879A1 AR102879A1 ARP150103939A ARP150103939A AR102879A1 AR 102879 A1 AR102879 A1 AR 102879A1 AR P150103939 A ARP150103939 A AR P150103939A AR P150103939 A ARP150103939 A AR P150103939A AR 102879 A1 AR102879 A1 AR 102879A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- brain cancer
- methods
- brain tumors
- car
- Prior art date
Links
- 208000003174 Brain Neoplasms Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 3
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Mycology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086346P | 2014-12-02 | 2014-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102879A1 true AR102879A1 (es) | 2017-03-29 |
Family
ID=56078487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103939A AR102879A1 (es) | 2014-12-02 | 2015-12-02 | Métodos para el tratamiento de tumores cerebrales |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9650428B2 (show.php) |
| EP (1) | EP3227317A4 (show.php) |
| JP (1) | JP2017537622A (show.php) |
| KR (1) | KR20180041087A (show.php) |
| CN (1) | CN107709353A (show.php) |
| AR (1) | AR102879A1 (show.php) |
| AU (1) | AU2015355084A1 (show.php) |
| BR (1) | BR112017011771A2 (show.php) |
| CA (1) | CA2969714A1 (show.php) |
| EA (1) | EA201791210A1 (show.php) |
| HK (1) | HK1251862A1 (show.php) |
| IL (1) | IL252610A0 (show.php) |
| MX (1) | MX2017007272A (show.php) |
| PH (1) | PH12017501031A1 (show.php) |
| SG (2) | SG10202103475XA (show.php) |
| TW (1) | TW201636425A (show.php) |
| UY (1) | UY36418A (show.php) |
| WO (1) | WO2016089916A1 (show.php) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9512194B2 (en) | 2012-01-27 | 2016-12-06 | The Board Of Trustees Of The Leland Stanford Junior University | Modified IL-13 polypeptides |
| CN104619334A (zh) | 2012-08-09 | 2015-05-13 | 利兰斯坦福初级大学董事会 | 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子 |
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| CA2925417C (en) | 2013-09-24 | 2023-10-24 | Fahar Merchant | Interleukin-4 receptor-binding fusion proteins and uses thereof |
| HK1251862A1 (zh) | 2014-12-02 | 2019-04-26 | 普拉斯派克特查特凯尔Rwmc有限责任公司 | 治疗癌症的方法和组合物 |
| EP3310805B1 (en) * | 2015-06-19 | 2021-02-17 | Kobold, Sebastian | Pd-1-cd28 fusion proteins and their use in medicine |
| MX382532B (es) * | 2015-08-05 | 2025-03-13 | Cellabmed Inc | Receptor de antigeno quimerico y celulas t en las cuales se expresa el receptor de antigeno quimerico. |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| US20200095301A1 (en) * | 2016-12-14 | 2020-03-26 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13 superkine: immune cell targeting constructs and methods of use thereof |
| CN110612119B (zh) | 2017-02-07 | 2024-10-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| CA3060443A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| AU2018347796B2 (en) | 2017-10-10 | 2025-07-24 | Medicenna Therapeutics, Inc. | IL-4-fusion formulations for treatment of central nervous system (CNS) tumors |
| MX2020005251A (es) * | 2017-11-20 | 2021-01-29 | Prospect Chartercare Rwmc Llc D/B/A Roger Williams Medical Center | Composiciones para mejorar la funcionalidad de células car-t y uso de las mismas. |
| CN118878697A (zh) * | 2017-12-20 | 2024-11-01 | 波赛达治疗公司 | Vcar组合物和使用方法 |
| CN120154716A (zh) | 2018-01-22 | 2025-06-17 | 恩多塞特公司 | Car t细胞的使用方法 |
| WO2019148006A1 (en) * | 2018-01-26 | 2019-08-01 | City Of Hope | Chimeric antigen receptors and methods for reducing off target toxicity |
| CN111936518A (zh) | 2018-02-06 | 2020-11-13 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car |
| CN110144326A (zh) * | 2018-02-12 | 2019-08-20 | 深圳宾德生物技术有限公司 | 一种靶向性抗肿瘤t细胞及其制备方法和应用 |
| CN110157674A (zh) * | 2018-02-12 | 2019-08-23 | 深圳宾德生物技术有限公司 | 一种靶向性t淋巴细胞及其制备方法和应用 |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| TW202000229A (zh) | 2018-02-23 | 2020-01-01 | 美商安德賽特公司 | Car t細胞療法之順序方法 |
| CN108440674A (zh) * | 2018-04-28 | 2018-08-24 | 杭州荣泽生物科技有限公司 | 一种Trop-2特异性嵌合抗原受体细胞制备及其用途 |
| WO2019239213A2 (en) | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
| CN115551882A (zh) * | 2020-01-31 | 2022-12-30 | 希望之城公司 | 用于治疗IL13Rα2阳性恶性病的靶向性嵌合抗原受体修饰的T细胞 |
| WO2021241719A1 (ja) * | 2020-05-28 | 2021-12-02 | 中外製薬株式会社 | 改良されたグランザイムｂ改変体 |
| JP2023539870A (ja) * | 2020-08-26 | 2023-09-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | グリア芽細胞腫を処置するための方法および組成物 |
| WO2022056398A1 (en) * | 2020-09-11 | 2022-03-17 | University Of Georgia Research Foundation, Inc. | Compositions and methods of use thereof for prevention and treatment of influenza infections |
| AU2021401052A1 (en) | 2020-12-18 | 2023-06-22 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CN118146395A (zh) * | 2021-02-08 | 2024-06-07 | 浙江大学 | 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体 |
| CN113304267B (zh) * | 2021-06-11 | 2022-03-15 | 河南大学 | 肺癌的治疗靶点及其应用 |
| CN114014941B (zh) * | 2022-01-10 | 2022-04-12 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的嵌合抗原受体及其用途 |
| CN116549667B (zh) * | 2023-05-29 | 2024-02-09 | 四川普锐特药业有限公司 | 一种pas修饰的脂质纳米粒、包含其的药物制剂，及其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965126A (en) * | 1996-03-25 | 1999-10-12 | The Penn State Research Foundation | use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents |
| JP2004500047A (ja) * | 1999-10-20 | 2004-01-08 | ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン | キメラ免疫原性組成物およびこれらをコードする核酸 |
| EP1480514A4 (en) * | 2002-03-01 | 2008-08-13 | Bristol Myers Squibb Co | TRANSGENIC NON-HUMAN MAMMALS EXPRESS CONSTITUTIVELY ACTIVATED TYROSINE KINASE RECEPTORS |
| WO2003086451A1 (en) * | 2002-04-05 | 2003-10-23 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
| US7709625B2 (en) * | 2004-06-10 | 2010-05-04 | The Board Of Regents Of The University Of Texas | Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy |
| BRPI0520686A2 (pt) * | 2005-11-16 | 2009-05-19 | Univ Mexico Nacional Autonoma | uso de agentes modificantes de transcriptoma associado a quimioterapia ou radioterapia contra o cáncer |
| CN101438158A (zh) * | 2006-03-06 | 2009-05-20 | 阿穆尼克斯股份有限公司 | 遗传包和其应用 |
| US20080206139A1 (en) * | 2006-11-03 | 2008-08-28 | The Penn State Research Foundation | Delivery system for diagnostic and therapeutic agents |
| EP4032552B1 (en) * | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| US9273283B2 (en) * | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| CA3002192C (en) * | 2010-03-26 | 2023-03-07 | Memorial Sloan-Kettering Cancer Center | Antibodies to muc16 and methods of use thereof |
| EP2931893A1 (en) * | 2012-12-13 | 2015-10-21 | Universität Leipzig | T-cell modulation by exon skipping |
| SI3613439T1 (sl) * | 2013-02-15 | 2021-11-30 | The Regents Of The University Of California | Himerni antigenski receptor in postopki njegove uporabe |
| WO2014164554A1 (en) | 2013-03-10 | 2014-10-09 | Baylor College Of Medicine | Chemotherapy-resistant immune cells |
| WO2015120363A1 (en) * | 2014-02-10 | 2015-08-13 | Emory University | Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer |
| HK1251862A1 (zh) | 2014-12-02 | 2019-04-26 | 普拉斯派克特查特凯尔Rwmc有限责任公司 | 治疗癌症的方法和组合物 |
-
2015
- 2015-12-01 HK HK18110565.4A patent/HK1251862A1/zh unknown
- 2015-12-01 CN CN201580074883.3A patent/CN107709353A/zh active Pending
- 2015-12-01 EA EA201791210A patent/EA201791210A1/ru unknown
- 2015-12-01 CA CA2969714A patent/CA2969714A1/en not_active Abandoned
- 2015-12-01 AU AU2015355084A patent/AU2015355084A1/en not_active Abandoned
- 2015-12-01 SG SG10202103475XA patent/SG10202103475XA/en unknown
- 2015-12-01 WO PCT/US2015/063267 patent/WO2016089916A1/en not_active Ceased
- 2015-12-01 SG SG11201704519YA patent/SG11201704519YA/en unknown
- 2015-12-01 MX MX2017007272A patent/MX2017007272A/es unknown
- 2015-12-01 EP EP15865800.5A patent/EP3227317A4/en not_active Withdrawn
- 2015-12-01 KR KR1020177018139A patent/KR20180041087A/ko not_active Withdrawn
- 2015-12-01 JP JP2017529284A patent/JP2017537622A/ja active Pending
- 2015-12-01 US US14/956,299 patent/US9650428B2/en not_active Expired - Fee Related
- 2015-12-01 BR BR112017011771A patent/BR112017011771A2/pt not_active Application Discontinuation
- 2015-12-02 TW TW104140317A patent/TW201636425A/zh unknown
- 2015-12-02 UY UY0001036418A patent/UY36418A/es not_active Application Discontinuation
- 2015-12-02 AR ARP150103939A patent/AR102879A1/es unknown
-
2017
- 2017-05-09 US US15/590,961 patent/US20180072789A1/en not_active Abandoned
- 2017-06-01 IL IL252610A patent/IL252610A0/en unknown
- 2017-06-02 PH PH12017501031A patent/PH12017501031A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG10202103475XA (en) | 2021-05-28 |
| IL252610A0 (en) | 2017-07-31 |
| CN107709353A (zh) | 2018-02-16 |
| CA2969714A1 (en) | 2016-06-09 |
| HK1251862A1 (zh) | 2019-04-26 |
| BR112017011771A2 (pt) | 2018-07-10 |
| KR20180041087A (ko) | 2018-04-23 |
| SG11201704519YA (en) | 2017-07-28 |
| US9650428B2 (en) | 2017-05-16 |
| EP3227317A1 (en) | 2017-10-11 |
| TW201636425A (zh) | 2016-10-16 |
| US20180072789A1 (en) | 2018-03-15 |
| AU2015355084A1 (en) | 2017-06-29 |
| MX2017007272A (es) | 2018-06-06 |
| UY36418A (es) | 2016-06-30 |
| EP3227317A4 (en) | 2018-04-25 |
| US20160151490A1 (en) | 2016-06-02 |
| JP2017537622A (ja) | 2017-12-21 |
| PH12017501031A1 (en) | 2017-11-27 |
| WO2016089916A1 (en) | 2016-06-09 |
| EA201791210A1 (ru) | 2017-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102879A1 (es) | Métodos para el tratamiento de tumores cerebrales | |
| ECSP18073836A (es) | Moléculas de unión a bcma y métodos de uso de las mismas | |
| CO2017010502A2 (es) | Receptores del antígeno quimérico dirigidos al antígeno de maduración de células b | |
| MX2024001192A (es) | Anticuerpos anti gen 3 de activacion linfocitica (lag-3) y metodos para usarlos. | |
| PH12017501115A1 (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and method of use | |
| CO2017010190A2 (es) | Terapias cd20, terapias cd22 y terapias de combinación con una célula que expresa un receptor quimérico de antígeno (car) de cd19 | |
| MX2016014000A (es) | Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer. | |
| PH12018501280A1 (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use | |
| MX2016014189A (es) | Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico. | |
| PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| MX2023000818A (es) | Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos. | |
| MX2017001011A (es) | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. | |
| AU2017228470A8 (en) | Combination therapy with anti-CD73 antibodies | |
| LT3183268T (lt) | Anti-cd123 chimerinis antigeno receptorius (car), skirtas naudoti vėžio gydymui | |
| MX2017001008A (es) | Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33. | |
| EA201790307A1 (ru) | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки | |
| AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
| PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
| MX2019013587A (es) | Proteinas agonistas del receptor del ligando que induce la apoptosis relacionada con el factor de necrosis de tumor de cadena individual. | |
| MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
| MX2018007818A (es) | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. | |
| MX382809B (es) | Uso de tm9sf4 como un biomarcador para exosomas asociadas con tumores. | |
| EA202092450A2 (ru) | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей | |
| AR106284A1 (es) | Terapias cd20, terapias cd22 y terapias de combinación con una célula que expresa un receptor quimérico de antígeno (car) de cd19 | |
| NZ761611A (en) | Single-chain trail-receptor agonist proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |